Composite preparation of polypeptide C16 and angiopoietin Ang-1 and its application

The liposome carrier modified by the leukocyte chemotaxis peptide fMLP carries a compound preparation of C16 and Ang-1, solving the problem of existing anti-inflammatory drugs crossing the blood-brain barrier, achieving safe and effective treatment of neurodegenerative diseases, and avoiding side effects such as systemic immunosuppression and phlebitis.

CN115737785BActive Publication Date: 2025-07-22ZHEJIANG UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202211422635.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-15
Publication Date
2025-07-22
Estimated Expiration
2042-11-15

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs have great side effects and are difficult to safely and effectively pass through the blood-brain barrier. The nano-drug-carrying system has limitations in stability and drug loading, which affects the effectiveness of treating neurodegenerative diseases.

Method used

A liposome carrier modified by coupled leukocyte chemotaxis peptide fMLP is adopted to carry a complex preparation of polypeptide C16 and angiopoietin Ang-1. The drug delivery system is optimized through nanomaterials to achieve targeted delivery of inflammatory sites, and combined with the anatomical characteristics of the blood-brain barrier to improve drug penetration efficiency.

Benefits of technology

It has achieved safe and effective penetration of the blood-brain barrier, reduced inflammatory cell infiltration, reduced systemic immunosuppression side effects, improved the therapeutic effect of drugs in neurodegenerative diseases, and reduced adverse reactions such as phlebitis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a composite preparation of polypeptide C16 and angiopoietin Ang-1 and its application. By taking advantage of nanomaterials and combining the anatomical and physiological characteristics of the blood-brain barrier, a new drug delivery system for the brain is developed to achieve the best effect of treating neurodegenerative diseases by penetrating the blood-brain barrier. It is a carrier that can target and transport drugs to the local inflammation. Liposomes modified with the leukocyte chemotactic peptide fMLP are a good choice for loading protein and polypeptide biological drugs, which solves the problem of drug administration of the Ang-1 + C16 composite drug.
Need to check novelty before this filing date? Find Prior Art